Фильтр

Фармацевтическая промышленность : обзор инвестиций и аналитика

(Данные обновляются)
Подотрасли: Лекарственные препараты - 219 (······) , Медицинские изделия - 103 (······)
Регионы: Московская область - 52 (······) , Москва - 26 (······) , Санкт-Петербург - 29 (······) , Калужская область - 13 (······) , Брянская область - 2 (······) , Кировская область - 4 (······) , Краснодарский край - 5 (······) , Башкортостан - 4 (······) , Мурманская область - 1 (······) Показать все...
Другие страны: Беларусь - 19 (······) , Узбекистан - 32 (······) , Казахстан - 25 (······) , Кыргызстан - 5 (······) , Азербайджан - 2 (······) , Таджикистан - 2 (······)
Период: 2021 - 2031
Холдинги:  112
Проектов по фильтру:  322 (757,9 млрд руб.)

Фармацевтическая промышленность — это сектор экономики, связанный с исследованием, разработкой и производством лекарственных препаратов.

По состоянию на октябрь 2025 в фармацевтической промышленности России насчитывается 235 проектов (активных и приостановленных) с объемом инвестиций 503,3 млрд руб. Интересантами реализации проектов выступают 100 крупных структур, которые занимаются финансированием, проектированием и строительством предприятий отрасли.

Для нового инвестора привлекательны ниши, пользующиеся максимальной государственной поддержкой и имеющие высокую маржинальность или социальную значимость.

  1. Производство активных фармацевтических ингредиентов (АФИ, субстанций): Критическая зависимость от импорта (более 80%). Государство предлагает беспрецедентные меры поддержки: субсидии, льготные кредиты, квоты в госзакупках. Это самая острая потребность всей отрасли.

  2. Биотехнологии и биоаналоги: Высокая добавленная стоимость и стоимость препаратов. В России сильная научная школа в этой области. Многие оригинальные биопрепараты иностранных компаний ушли с рынка, образовав нишу для высокомаржинальных биоаналогов (например, препараты для лечения онкологии, аутоиммунных заболеваний).

  3. Ветеринарная фармацевтика: Растущий рынок, менее регулируемый, чем "человеческая" фармацевтика. Высокий спрос со стороны агропромышленного комплекса и владельцев домашних животных. Уровень импортозависимости также очень высок.

  4. Контрактное производство (CMO): Многие иностранные компании, желающие остаться на рынке, переходят на модель контрактного производства с местными партнерами. Также российские компании, не имеющие собственных мощностей, ищут подрядчиков. Создание modern GMP-совместимого завода под контракты — очень востребованная услуга.

.......................... .......... .... .................. .... .............. .... ........

.. .. .. .. .. ....

........ ................. ............ .................... .. ............................... ....................... ..............

.. .. .. .. .. .. .. .. .. .. ....

Динамика рынка

.......... ........................ ............ .. .... ... .................. .. ........ ................ ........................... ........................ .......................... ............... .................. ................................ .. .......... .................................... .......................

  • .......... .......... .. .................. .......... .... ............ .... ... ................ ......... ........ ....... ........ ................ .......... ... .. .. ............ .............. .................... .................. .. ...................... ...... .. ............ .....................

  • .......... .. ...................... .................. ............ ................. .................. ........................ ..................... ...... .............................. .. ...... .................. .. .................

.... ............ .... ... .................. ........ .... ............ ........ ...... .......... .............. .. ........................ .. .................................. .................. .................... ..................... .................... ................................ .......... .................... .................... ....................... .. ................ .................. .. .................. ................................. .................... .................. ...................... .... .. .............. ...................... .............. .. .......... ..................... .. .. ................ ................ ...................... .. .............. ........................ ..................... .......................... .. .............. .......................... .........

.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..

Импорт

............ ................ .................... ............ ...... ........... .... ...... .................. .. .................. ...................... ......................... ................ .................. .......... .............. .............. ................ .. .................... ...................... .... .............. ............. ...... .................... .............. .. ........ .................

.................. ..................................................... ................... .............. .......... ........................ .... .......... .... .. ....... ............ .......... ................ .....

  • ............................. .................. ............................ .. .............. .....................

  • ................................. .............. .... .............. .................... .. ................ ................................ ........................ .........

  • .......... ............. ............ .............. ................ .. .................... .......... ........................ ...... ............ ...... .................. ...... ...................... ...................

  • ............. ............... ............................... .......... .......................

.. .. .. .. .. .. .. .. .. .. ....

Проблематика определения объемов производства российского происхождения

.. .................. .......... ...... ...................... .......................... .............. .. ........................ .... ...................... .... ................ .............. .................................. ........... .............................. .......................... ............................ .................. .. .............................. ............ ............ ................. ........ ........ .... .................... ............ ............................ ........ ...... ................ .. ................ ................. ...... .............. ........ .................... ................ ...................... .................. .................. ............... ........ .. .............................. .......................... ...... .............. ............ ...... ............ ................ ..... .... ................ .......................... .................. ...........................

.......... ............................ ............................ ............. ...... .............. .............................. .......................... ................ ...... ............. ...... ...................... ................................ ..................... .......... ............... .............................. .......................... .. .............................. ............ ............ ............ ........ .......................... ............ ...... ................ .............. ........... .......... ............................ ........................ .............................. .. ............. .. .... ................ ......... .............

...... ............ .......... ............ ................ ...... .................... ................................ .......................... ............. ...... .. ............ .............. .................... ...... ...................... .................. .. ............................ ...................... .................. ........................ ........................... ............ ........ ........................ .................. ............................ ................ .... ........ ............ .. .............. ...................... .... .............. .......................... .. ........................ ..................... ...... ............................ .............. ........................ .. .................... .............. .... .......... .......................... ...............

.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..

Экспорт

.. .................... .............. ................ .............. .............. .................... .......................... ............... .......... ................ .................... .......................... .............. .. .... .... .... ............ ........................ ..... ................ ... ........ ....... .................. .......................... ...... ................ ...................... ................ ............ ....... .......... ...... ................... ................ .. ..................... .......... ......... .......................... .. .............................. .............. .......... .................... ............ ................ ............... ............ .. ......................... ......... ........................ ............ .. ................ ................... .... ........ ................................ ................... .................... .. ...............

.. .. .. .. .. .. .. .. .. .. .. .. .. .. ..

Лекарственные препараты — в топе отраслей РФ по объему инвестиций

.. ............ .................... ........................ .................. .. ...................... .......... .................. .......................... .................... .. .................. ...................... ............... .................... .. .................. ...................... .................. ................ .. ...................... ...............

.............. .................. .......... .................................................. ................. ............................ .................. ................. .......... ...... ................... .. ...................... ............ .................... .................... .......................... ............ .... .......................... ................... ...... .................... ............................ ............ .. ................ .................. ................... ................ ............................. .......... ...... ...................... ...... ............................ .................. .. .................... .................. .......................

.......... ........................ .................... .............. .. .................. ...................... .................. .. ............... ................ .................. ...................... ........................... ...................... .... .............. ...................... ............... .... .......... ...................................... ................. .......... ...... ................ ....... ..... .................... .. ...................... .............................. ......................... ........ .............. .................. ......... ...... .................................... ........................ .............. .................................................... .................... .... ...................... .. .............. ................................. ..............................

.. .. .. .. .. .. .. .. .. .. .. .. .. ..

Регион — лидер по объему инвестиций

.. .................... .............. .... ................ .............. .................. .. ................. .......... .......... .................... .. .............. ...................... .. .... ........ .......

.. ....................... .... ................ ...... ...................... .............. .. ................... .......... .................... ............ .............. .. ............ ........................ .... .............. .............. .................... .... ............ .......... ................ ... .................. .. ............................... ................ ...................... ................ ............................ ......... .. ............ .. ....... ...... ...................... .................. .............. .............. ...................... ............ .. ........ ................... .......... .......... .................... .. ............ .................. .. ........ ....... .... .................... .............. .................... .......... ........ .................... .............. .............. .... ............... .. ................ .... ...................... .................................................. .................... .... ................ ........ .............. ................................. ..............................

.. .. .. .. .. .. .. .. .. .. .. ....

Структура инвестиций по стадиям

.... ............ .............. .................. ... ................ .............. .... .......... ..... ........ ....... ....... .................... ........ ............ .................... .......... .. .............. .................. ................................ .................... ...... ............... ....... ................ .. ............................ ....................... .. ............ ................ .. ............ .......... ............ ...................... ................................ ................. .......... .......... .................... .. ............ .... ............ .......... ...................... ...... ........ ........ .... .............. ........ ...................... ......... ........ ....... ............ ............................................ ................................ ............. .... .............. .................... .... .............. .............. .................

................ ............................ ............ ........ .. ...... ............... ... ...... .............. .. ........................ ...... .. ................ .................... ......................... .... .................. .... ................ .......... .................... ....................... ...................... .... .............. .............. ........................ .................... ... ...... ...... ............. .... .............. ..................... ...... ............................ .......... .. ...................... .... ...............

.... .......... .............. .............. ... .......................... .. ........................ ... .................. ..... ................ .................... .............. .................... .......... ..... ........ ....... ................... .................... .... .................. .............. ................................. ..............................



Новости холдингов отрасли
  • 04.04.2025

    Указом Президента Российской Федерации ООО «Фармирус» назначено управляющим 100%-м пакетом акций АО «Нижфарм».

    Комментарий ПКР: это решение усиливает контроль над стратегически важными российскими предприятиями и имеет долгосрочные перспективы для развития фармацевтической отрасли России.

  • 14.03.2025
    ···· ······················-··········: ······················ ·············· ········ ········ ···· ························································.·················································· ···························· ···································· ················ ········ ···· ························································.·············································· ···················· ···················································· ························································.·························································· ·················································· ·· ·················· ···· ························································.······················································ ·················· ································ ························ ···· ······················ ·············· ·················· ················ ···· ························································.······················································ ·················· ································ ·· ···· ························································.·············································· ···················· ·························································· ···· ······················-··········: ········································ ········ ······ ·············· ·········· ················ ·· ···················· ·············· ························ ················ ···· ·········· ·· ························ ················ ·················· ······················ ···················· ························ ··························
  • 22.10.2024
    ···· ······················-··········: ························ ························································.···················································· ···················································· ·················· ········ ·········· ·················· ················ ···· ························································.························································ ························ ······································ ···················· ································ ·········· ·· ································ ······················ ·· ·········································· ···· ······················-··········: ·········································· ········ ························ ···· ························································.························································ ························ ···································· ·················· ······ ···· ························································.···················································· ···················································· ·········· ······················ ···· ································ ············ ·············· ············ ·········· ·········· ···························· ·········· ······ ···························· ·············· ·· ···················· ·············· ···· ·········· ·························· ······························
  • 18.04.2024
    ·························· ································ ·············· ···· ························································.·································································································· ·········· ············ ·························· ·················· ·················· ·················· ···· ········ ·············· ·················· ················ ·· ············ ·························· ···························· ········ ···· ························································.·································································································· ·················· ················ ············ ·················· ······························
  • 28.06.2023
    ······················ ·················· ············ ···· ···················· ·························· ···································· ·· ···························· ···· ························································.····························-··········-···························· ························ ················ ······ ·········· ·········· ·· ···· ························································.·················································································· ·········· ···· ························································.·········································································· ················ ································ ···· ······················ ························ ······ ························ ························ ·· ·············· ·· ················ ·················· ···· ·· ········ ········ ·················· ······ ·········· ·············· ·· ···················· ······················ ············ ···· ·········· ···················· ·················· ·· ······················ ···························· ········ ················ ······ ························································.·············································································· ················ ···· ·············· ················ ···· ························································.····························-··········-················································
  • 28.02.2023
    ········ ·············· ········ ········ ················ ················ ···· ························································.·············································· ························ ···· ························································.············································································ ·········· ···················· ·········· ·········· ·· ···· ························································.························································ ······················ ······ ······················ ·················· ······························ ·· ···· ························································.······································-·························· ·················· ···························· ······ ········ ········ ·· ············ ·············· ···· ························································.·································································· ·········· ········ ···················· ·························· ···················· ···· ························································.················································································ ···························· ········ ···· ························································.························································ ···················· ·················· ························································.························································ ···················· ···················· ·· ············ ················ ···· ························································.············································································
  • 03.10.2022
    ················ ·································· ························································.·········································································· ·············· ········ ·········· ·························· ············ ······ ························································.·········································································· ······ ······················ ·· ···· ················ ·· ·············· ·········· ······················ ········································ ················ ···················································· ········ ······ ························································.·········································································· ················ ·· ·············· ················ ···· ························································.··································································································
  • 22.09.2022
    ······················ ······ ························································.········································-······································ ························ ·············· ·················· ························································.········································································ ························ ······················ ·· ·············· ································ ·················· ········ ·· ···································· ·············· ························ ·· ···················· ·················· ···················· ···· ············ ······················ ················ ·· ·················· ·················· ···················· ················ ······················ ·················· ···························· ········ ············ ·············· ···· ························································.········································-········································ ·························· ·· ········ ·················· ············ ····························
  • 01.09.2022
    ········ ················-··················-·················· ························································.···························································································· ·············· ···················· ·········· ········ ·········· ························ ···· ························································.······································································ ·· ························ ·················· ·············· ················ ·············· ·············· ········ ·· ················ ············ ·········· ·········· ················ ·· ·············· ···· ·············· ·· ·············· ········ ········ ······················ ·············· ···· ··········-···· ···························· ················ ·················································· ········ ······ ························································.···································································· ················ ·· ············ ················ ···· ························································.····················································································································
  • 29.08.2022
    ·································· ·············· ···· ························································.······································-···························· ······················ ·············· ·· ···· ·············· ·············· ······················ ·············· ········ ·········· ················ ·········· ······························ ················ ······················ ······ ······································ ············································ ···························· ········ ······················ ···················· ···· ························································.······································-···························· ························ ·· ········ ·················· ················ ········ ······ ················ ································
  • 21.07.2022
    ········ ···················· ················ ·········· ·············· ···· ························································.·················································· ······························ ······························································ ······ ······················ ························ ················ ················ ················ ···· ································ ·············· ·· ·········· ······ ······ ···················· ···························· ········ ············ ·········· ·············· ···· ························································.····························································································
  • 04.02.2022
    ································ ·············· ···· ························································.·································································· ············ ············ ···· ·············· ························ ············ ·········· ···················· ················ ········ ···· ························································.·············································································· ···· ············ ········ ················ ················ ·············· ········ ·················· ···· ························································.············································································ ············ ···· ·········· ············ ················ ········ ·· ············ ·········· ···· ························································.····································-········································ ·· ················ ············ ············ ·············· ···················· ················ ·· ······································ ···························· ········ ···· ························································.············································································ ················ ·· ············ ················ ···· ························································.·································································· ·· ················ ································

  • Топ крупнейших групп проектов в отрасли "Фармацевтическая промышленность"

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Проекты в отрасли "Фармацевтическая промышленность"

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Инвестиции в проекты по годам в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** В зависимости от примененных фильтров по умолчанию может выводиться ТОП-8 категорий. Для выбора остальных категорий воспользуйтесь легендой под графиком

    Структура инвестиций по подотраслям по годам в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Ввод в эксплуатацию (и прогноз ввода) проектов по годам в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтр учитывает все стадии проектов, кроме «приостановлен».

    Структура инвестиций по подотраслям в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП подотраслей. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Структура инвестиций по регионам РФ в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП регионов. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Структура инвестиций по ФО в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Структура инвестиций по видам собственности в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Структура инвестиций по стадиям в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры выстроены от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Структура инвестиций по размерности проектов в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Инвестиционная активность за 12 месяцев в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Количество и стоимость проектов на активной стадии (без приостановленных) в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Количество и стоимость проектов на стадии Приостановлен (накопительным итогом) в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Динамика добавления новых проектов на платформу в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Динамика ввода проектов в эксплуатацию в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Динамика приостановки проектов в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Приостановка проектов по месяцам в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Динамика выхода проектов из приостановки в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Динамика отмены проектов в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Топ инвесторов проектов в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Крупные инвесторы проектов в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП инвесторов. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Топ генеральных проектировщиков проектов в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Генеральные проектировщики в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП генпроектировщиков. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Топ генеральных подрядчиков проектов в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Генеральные подрядчики в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП генподрядчиков. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Структура инвестиций в иностранной собственности без российских бенефициаров в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Российские инвестиции в другие страны в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Площадь объектов по ФО в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Площадь участков проектов по ФО в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Совместные инвестиции России и в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Интеграция через технологии и строительство (Генпроектировщик, Генподрядчик, Проектировщик, Субподрядчик) Территория – Россия, исполнители в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Интеграция через технологии и строительство (Генпроектировщик, Генподрядчик, Проектировщик, Субподрядчик) Территория в отрасли "Фармацевтическая промышленность", исполнители – Россия (Данные обновляются)

    Основные холдинги-инвесторы в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Основные холдинги-инвесторы в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Динамика выручки холдингов инвесторов отрасли в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Инвестиции в проекты по годам в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Крупные инвесторы проектов в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Генеральные проектировщики в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Генеральные подрядчики в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Структура инвестиций по стадиям в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Структура инвестиций по видам собственности в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Структура инвестиций по регионам в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Проекты по параметру "Вид контракта" в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    "Вид контракта" по ФО в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    в отрасли "Фармацевтическая промышленность" (Данные обновляются)

    Графики по Вашему запросу отсутствуют.

    Вы можете посмотреть другие графики во вкладке «Вид контракта» по Вашему запросу.
    Показать